Oryon Cell Therapies
Oryon Cell Therapies
Clinical-stage biotechnology company developing autologous neuron replacement medicines for neurodegenerative disorders.
About
What does Oryon Cell Therapies do?
Oryon Cell Therapies is a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders. The company has emerged from stealth and secured significant funding to advance its therapeutic programs.
What is Oryon Cell Therapies's revenue?
StartupHub estimates Oryon Cell Therapies's annual revenue at $2.3M (range $752K to $9.2M, 34% confidence), based on comparable companies in the sector.
What is Oryon Cell Therapies's valuation?
StartupHub estimates Oryon Cell Therapies's effective valuation at $89.0M (range $52.5M to $126.0M, 23% confidence), based on comparable companies in the sector.
How much funding has Oryon Cell Therapies raised?
Oryon Cell Therapies has raised a total of $21M in funding. The most recent round on record is Series A.
Where is Oryon Cell Therapies headquartered?
Oryon Cell Therapies is headquartered in Belmont, Massachusetts, USA.
What industry does Oryon Cell Therapies operate in?
Oryon Cell Therapies operates in Biotechnology, Health, Neuroscience, Cell Therapy.
What is Oryon Cell Therapies's current status?
Oryon Cell Therapies's current operating status is: Inactive.
Galatek develops AI-driven automation solutions for life sciences laboratories and advanced semiconductor manufacturing, focusing on precision and reproducibility.
Digital batch record software for pharmaceutical and biotech manufacturing.
Develops and commercializes treatments for central nervous system disorders, including Rett syndrome.
A deep-tech company developing nanorobotic solutions for healthcare, initially targeting dental care applications.
MatrixCode is a research focus at the Freiburg Institute for Advanced Studies (FRIAS) investigating matrisome pathology.
A company focused on privacy, Zcash accumulation, and developing cancer therapeutics.
An entrant is a company tagged Biotechnology whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.

